Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total revenues	$ 14,177,000	$ 3,828,000	$ 24,832,000	$ 12,743,000
Operating expenses:
Cost of sales	4,292,000	155,000	5,680,000	155,000
Research and development	40,237,000	55,273,000	166,744,000	135,210,000
Selling, general and administrative	38,792,000	28,856,000	110,547,000	64,206,000
Total operating expenses	83,321,000	84,284,000	282,971,000	199,571,000
Loss from operations	(69,144,000)	(80,456,000)	(258,139,000)	(186,828,000)
Interest and other income, net	3,924,000	663,000	9,123,000	952,000
Interest expense	(5,957,000)	(3,148,000)	(12,642,000)	(8,243,000)
Net loss	(71,177,000)	(82,941,000)	(261,658,000)	(194,119,000)
Net (income) loss attributable to noncontrolling interest (SRX Cardio)	(126,000)	5,000	(17,000)	(190,000)
Net loss attributable to Portola	$ (71,303,000)	$ (82,936,000)	$ (261,675,000)	$ (194,309,000)
Net loss per share attributable to Portola common stockholders:
Basic and diluted	$ (1.08)	$ (1.41)	$ (3.97)	$ (3.38)
Shares used to compute net loss per share attributable to Portola common stockholders:
Basic and diluted	66,165,104	58,940,764	65,855,672	57,569,593
Product Revenue, Net
Revenues:
Total revenues	$ 7,176,000		$ 10,047,000
Collaboration and License Revenue
Revenues:
Total revenues	$ 7,001,000	$ 3,828,000	$ 14,785,000	$ 12,743,000